Q-omics provides the consensus-scored SYNGR2P1 profile across patient tissues and cancer cell-line models. SYNGR2P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SYNGR2P1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SYNGR2P1 RNA expression shows 12,129 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, HNSC, and KIRP as cancer lineages where SYNGR2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNGR2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNGR2P1 survival associations across molecular data types. SYNGR2P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNGR2P1 RNA expression–survival associations across cancer types. High SYNGR2P1 expression shows unfavorable associations in UVM, MESO, KIRP and LIHC, but favorable associations in SKCM and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SYNGR2P1 RNA expression.
This table summarizes SYNGR2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SYNGR2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNGR2P1 shows lower tumor expression in KICH and higher tumor expression in HNSC, BRCA, LIHC, COAD and KIRC. The HNSC box plot shows higher SYNGR2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p = .001).
This table shows molecular features associated with SYNGR2P1 in patient tissues and cancer cell lines. In patient samples, SYNGR2P1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
